iVigee reports that the Medicines Evaluation Board in the Netherlands has updated its policy on additional risk minimisation measures.
Public source
Publisher name
Public post
Two regulatory updates to watch this week if you file in China or market in the Netherlands. 🇨🇳 China: The Center for Drug Evaluation has opened a public consultation…
Company
iVigee
- Industry
- Biotechnology Research
- Location
- Burlington, US
- Company size
- 51–200 employees
About iVigee
iVigee delivers physician-led pharmacovigilance grounded in truth. You receive pharmacovigilance services and consulting across the entire product lifecycle, from clinical development through post-marketing authorization. Our approach is built on transparency, regulatory realism, and straight answers you can trust, so you’re never left guessing. You work with physicians, former regulators, EU QPPVs, and senior safety leaders who understand how pharmacovigilance is evaluated in real inspections. We focus on what regulators actually look for, what they question, and what they expect you to explain, not just what guidance says. We support you as you build, optimize, and transform your pharmacovigilance capabilities, providing clarity at every stage, from early system design through mature, inspection-ready operations. Across everything we do, you always know where you stand, before inspections, before submissions, and before issues become findings. iVigee operates under an ISO 9001: 2015 – certified quality management system, ensuring the way we work is as structured, consistent, and accountable as the systems we help you establish and maintain.
See moreLatest activity
Latest activity from iVigee
13 signals
Presence & Recognition
iVigee hosted a conversation between Henry Seto and Jan Petracek discussing how AI is changing pharmacovigilance work and supervising it.
Presence & Recognition
iVigee hosted a conversation with Henry Seto discussing AI taking over daily pharmacovigilance work and supervising it.
Research & Knowledge
iVigee published the Netherlands policy on risk minimization measures
Discover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
Citeline
Citeline learned that the European Medicines Agency is preparing to pilot a new agile scientific advice pathway in Q1 2027.
Legal & Regulatory
Sano Genetics
Sano Genetics notes that the FDA recently opened the door a little wider for drugs to reach approval on a single clinical trial, with new draft guidance clarifying when a well-controlled trial can be enough to prove a drug works.
Legal & Regulatory
CN Bio
CN Bio notes that the EMA has announced a new voluntary data submission pilot designed to help regulators gain experience with New Approach Methodologies (NAMs), including microphysiological systems, organoids, and computational approaches.
Legal & Regulatory
Paul-Ehrlich-Institut
Paul-Ehrlich-Institut announced that the change in the Application Process for Processing Numbers (ENR) and EU Procedure Numbers (EUV) comes into effect today, effective from 1 September 2026, replacing the previous application process by email.
Legal & Regulatory
Horizon